Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06399952 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06399952 · ClinicalTrials.gov record · last posted 2026-06-03

Baker Gordon Syndrome Natural History Study

Study acronym: BAGOS
StatusRecruiting
PhaseNot specified
Started2024-04-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2024-05-01; most recent amendment 2026-06-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06399952
Lead Sponsor University of Missouri-Columbia
Conditions Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Enrollment 50 participants
Start Date 2024-04-30
Primary Completion 2027-05-05 (estimated)
Study Completion 2027-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-03